# A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

> **NCT00679627** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 2051 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Galantamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00679627
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-05
- **Target enrollment:** 2051 (ACTUAL)
- **Why stopped:** Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early termination of the trial
- **Last updated:** 2013-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679627, "A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00679627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*